Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Transaction by Person Discharging Managerial Responsibilities Disclosure Rule DTR 3.1.4 On 27 October 2015, Jean-Philippe Courtois, a Director of the Company notified us that, on 6 August 2015, he...
-
AstraZeneca has announced that the US Food and Drug Administration's (FDA) Arthritis Advisory Committee (AAC) voted 10 to 4 to recommend the approval of lesinurad 200mg tablets for the treatment of...
-
AstraZeneca (http://www.astrazeneca.com/) today announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for the...
-
The 'Holding(s) in Company' announcement released on 08 October 2015 at 17.29 was released in error and should be disregarded....
-
Please refer the pdf attachment....
-
ASTRAZENECA COMPLETES DIVESTMENT OF RARE DISEASE MEDICINE CAPRELSA AstraZeneca has announced the global completion of the divestment of Caprelsa® (vandetanib), a rare disease medicine, to Genzyme, a...
-
Transaction by Person Discharging Managerial Responsibilities Disclosure Rule DTR 3.1.4 On 1 October 2015, the interest of Mr Pascal Soriot, a person discharging managerial responsibilities, in the...
-
Transactions by Person Discharging Managerial Responsibilities Disclosure Rule DTR 3.1.4 On 25 September 2015, Dr Sean Bohen, EVP, Global Medicines Development & Chief Medical Officer, a person...
-
Transactions by Person Discharging Managerial Responsibilities Disclosure Rule DTR 3.1.4 On 28 September 2015, Marc Dunoyer, Chief Financial Officer, a person discharging managerial responsibilities,...
-
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved BRILINTA® (ticagrelor) tablets at a new 60mg dose to be used in patients with a history of heart attack beyond...